Lv31
274 积分 2022-09-05 加入
Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?
38分钟前
待确认
Building the future management of follicular lymphoma with T-cell–redirecting strategies
2小时前
已完结
Frontline treatment of follicular lymphoma: What will it take to change current practice?
2小时前
已完结
The future of follicular lymphoma management: strategies on the horizon
7小时前
已完结
Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?
7小时前
已完结
The present and future for CAR-T cell therapy in adult B-cell ALL
1个月前
已完结
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment
2个月前
已完结
Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation
3个月前
已完结
High-Risk MCL: Recognition and Treatment
3个月前
已完结
Prognostic Biomarkers in MCL: Insights from the SHINE Trial on the impact of MCL35 score and TP53 Mutation Status
3个月前
已完结
皖公网安备34019202002308
